** EXANE BNP Paribas re-evaluates companies in Medtech and Services sector, shifts preference to Demant DEMANT.CO from Sonova SOON.S
** Raises Danish hearing solutions provider Demant to "outperform" from "neutral", saying new product cycle in H2 will end a two-year EPS downgrade trend
** But cuts Sonova to "underperform" from "outperform", citing easing tailwinds from co's latest product launch, limited catalysts and competitive pressure
** Brokerage cautious about Sonova's "ambitious" outlook; says management transition phase introduces potential operating momentum volatility
(Reporting by Anastasiia Kozlova)
((Anastasiia.Kozlova@thomsonreuters.com))